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BRIEF REPoRT
Introduction: The study of patients carrying germline endothelial 
growth factor receptor (EGFR) mutations, which have been found in 
cases of familial lung adenocarcinoma, could provide unique insight into 
lung cancer risk and carcinogenesis in never-smokers. However, inves-
tigations into the biology of germline EGFR mutations have been ham-
pered by the lack of an effective strategy for screening for carriers. We 
hypothesized that patients with lung cancers found to harbor the EGFR 
T790M resistance mutation before treatment, an uncommon occurrence, 
would be likely to carry underlying germline T790M mutations.
Methods: Eleven unrelated patients with lung cancer, harboring 
an EGFR T790M mutation, were identified from a 7-year institu-
tional experience with tumor genotyping. Ten patients had benign 
tissue available, which was anonymously tested for the presence of 
germline EGFR mutations.
Results: Five of 10 cases carried a germline T790M mutation (50%, 
confidence interval 27%–73%). one patient’s cancer exhibited a dis-
tinctive indolent growth, which has also been described in preclinical 
studies of T790M-mutant cancers. A second patient underwent resec-
tion of six separate primary lung adenocarcinomas, each carrying 
different sensitizing EGFR mutations and T790M.
Conclusions: Genotyping of lung cancers, now commonly per-
formed to predict benefit from treatment with EGFR tyrosine kinase 
inhibitors, can also be used as a screening tool to identify patients 
at risk of carrying germline EGFR mutations. once identified, these 
patients and their families can be studied prospectively to explore 
appropriate lung cancer screening strategies. Further studies using 
existing oncogenomic data to provide insight into underlying ger-
mline genetics are warranted.
(J Thorac Oncol. 2012;7: 1049–1052)
The frequent identification of endothelial growth factor receptor (EGFR) mutations in lung cancers in never- 
smokers has added complexity to our understanding of lung 
cancer risk and predisposition. The most important risk fac-
tor for the development of lung cancer is clearly a history of 
smoking; indeed, studies have found that the gene most asso-
ciated with lung cancer risk is one that influences nicotine 
metabolism.1 yet risk factors for the development of lung can-
cer in never-smokers are less clear. As smoking rates decrease, 
lung cancer in never-smokers may come to represent a larger 
proportion of this deadly disease, necessitating an improved 
understanding of risk factors for its development.
Germline EGFR mutations, which have been identi-
fied in cases of familial lung adenocarcinoma,2,3 have the 
potential to provide insight into EGFR-mutant lung can-
cer risk and carcinogenesis. However, because there is no 
effective strategy for screening for these mutations, only a 
small number of affected families have been identified since 
germline EGFR mutations were first described,2 impairing 
our ability to study this phenomenon. one study found no 
cases of germline T790M among 52 families with at least 
three relatives with lung cancer,4 yet 86% of this cohort had 
smoked, and adenocarcinoma predominated in only three 
families.5 Another study screened peripheral blood from 369 
never-smokers with lung adenocarcinoma and found two 
cases of germline T790M (0.5%) in this clinically selected 
population.6
Interestingly, EGFR T790M is also rare in unselected 
lung cancer patients at diagnosis,7 although T790M is com-
mon after cancers develop resistance to EGFR tyrosine kinase 
inhibitors (TKIs) such as erlotinib.8 Now that EGFR genotyp-
ing is a standard part of the management of lung adenocarci-
noma, baseline T790M mutations are occasionally identified 
during patient care, but the optimal management of such cases 
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is not clear. We hypothesized that germline testing of these 
patients harboring baseline T790M mutations would be an 
effective way of screening for patients with underlying ger-
mline T790M mutations in EGFR.
METHODS AND RESULTS
Through an institutional review board-approved mecha-
nism, we identified 11 unrelated lung cancer patients whose 
tumors harbored a baseline T790M mutation, from a total of 
503 patients with EGFR-mutant lung cancer treated at our 
institution over a 7-year period.9 Nine cases were identified 
incidentally through routine sequencing of EGFR or through 
the use of a mass spectrometry-based assay. The other two 
cases, known to harbor a sensitizing EGFR mutation from a 
mutation-specific assay, were subsequently found to harbor 
a concurrent pretreatment T790M using directed testing of 
EGFR exon 20.10 To rule out false positive T790M results, all 
cases had the presence of the baselineT790M mutation con-
firmed with Sanger sequencing. All 11 tumors also carried 
a concurrent sensitizing mutation in EGFR (Table 1). Five 
patients were treated with EGFR TKI at some point in their 
course and none had a response; this was consistent with the 
expected resistance.7
For the 10 patients with benign tissue available, Sanger 
sequencing of EGFR was performed on extracted DNA, in 
an anonymized fashion. Benign specimens included periph-
eral blood (n=3), benign resected lung or lymph nodes tis-
sue (n=5), or other benign biopsies (skin and trachea). To 
rule out contamination from lung cancer cells in the benign 
specimens, all were confirmed to be negative for sensitizing 
EGFR mutations. A germline T790M mutation was identi-
fied in the benign tissue from five of the 10 patients (50%, 
confidence interval 27%–73%; Table 1); all five mutations 
were heterozygous. Two of the five patients with germline 
T790M had a family history of lung cancer in a first-degree 
relative.
Although pedigrees could not be collected because of 
the anonymized design of the study, one patient with a sibling 
with lung cancer later was confirmed to carry germline T790M 
in her peripheral blood. This never-smoker had initially been 
diagnosed with advanced lung adenocarcinoma when a lung 
resection demonstrated multifocal disease. Because of her low 
tumor burden in the lungs only, the patient opted for a strat-
egy of expectant observation. After 4 years of observation, the 
patient’s lung lesions grew minimally (Fig. 1A); repeat biopsy 
again showed adenocarcinoma harboring concurrent L858R 
and T790M EGFR mutations despite no exposure to TKI. We 
suspect that the slow growth seen may be related to the indolent 
biology reported in cancers that acquire the T790M resistance 
mutation.8,11 In retrospect, we found that the sequencing tracing 
from the patient’s tumor demonstrated a T790M mutant allele 
present in equal proportion to the wild-type allele, consistent 
with our subsequent finding of a germline mutation (Fig. 1B). 
In contrast, when T790M is only detectable with a highly sen-
sitive assay (likely indicating the T790M is present in a minor 
clone),10 a germline mutation may be unlikely.
A second patient tested positive for germline T790M 
after resection of multiple morphologically distinct lung 
adenocarcinomas carrying different EGFR genotypes. This 
never-smoker was initially diagnosed with advanced lung 
adenocarcinoma after a computed tomography showed mul-
tiple lung nodules and a biopsy found adenocarcinoma har-
boring a sensitizing EGFR mutation. Because of her young 
age, she was offered resection of her remaining lung nodes 
as these nodules potentially represented synchronous pri-
mary lung cancers. Six different nodules were resected, each 
exhibiting different adenocarcinoma morphologies. on EGFR 
genotyping, four carried L858R, two carried different exon 19 
deletions, and all carried T790M as well. Interestingly, this 
patient had no family history of lung cancer, suggesting either 
an inherited T790M mutation with variable penetrance or a de 
novo germline mutation.
DISCUSSION
We have found that patients with germline EGFR T790M 
mutations, which have been found in association with famil-
ial lung adenocarcinoma, can be identified through screening 
patients whose tumors harbor baseline EGFR T790M muta-
tions on routine lung cancer genotyping. Estimating that 1% 
of EGFR-mutant lung cancers harbor T790M at diagnosis,7 we 
suspect that approximately 200 patients are diagnosed annu-
ally in the United States with lung cancers carrying baseline 
EGFR T790M. Because EGFR genotyping is now a standard 
part of the management of patients with non–small-cell lung 
cancer, identification of patients with baseline T790M will 
be part of routine oncological practice and could be consid-
ered for referral for germline testing. Importantly, because 
germline mutations are present in both benign and neoplas-
tic cells, they should be easily detected using standard Sanger 
TABLE 1. Characteristics of All Patients and Germline Casesa
Characteristic
All Patients  
(N = 11)
Germline Cases 
(N = 5)
Age at 
diagnosis
Median (range) 56 (44–75) 56 (44–73)
Smoking 
history
Never-smoker 6 (55%) 4 (80%)
Former/current smoker 5 (45%) 1 (20%)
First-degree 
relative with 
lung cancer
Present 3 (27%) 2 (40%)
Absent 8 (73%) 3 (60%)
Stage I 2 (18%) 1 (10%)
II 1 (9%) 0 (0%)
III 0 (0%) 0 (0%)
IVb 8 (73%) 4 (80%)
Histology Adenocarcinoma 11 (100%) 5 (100%)
EGFR 
sensitizing 
mutation
Exon 19 deletion 4 (36%) 2 (40%)
Exon 21 L858R 6 (55%) 2 (40%)
Different mutations in 
different lesionsb
1 (9%) 1 (10%)
No sensitizing mutation 0 (0%) 0 (0%)
EGFR, endothelial growth factor receptor.
aTwo of these patients have been previously reported as part of a separate study.6
bone patient had multiple pulmonary nodules harboring different EGFR sensitizing 
mutations in addition to T790M, possibly representing multiple primary lung cancers 
rather than stage IV disease.
1051Copyright © 2012 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology  •  Volume  7, Number 6, June 2012 Screening For Germline EGFR Mutations
sequencing. The detection of T790M only with the use of the 
highly sensitive assays recently developed10,12,13 would not 
be associated with an underlying germline mutation as this 
suggests that the mutation is only present in a very small 
proportion of the cells tested.
The idea of using routine tumor genotyping, performed 
for treatment planning, as an initial screen for patients likely 
to harbor germline mutations has not been described previ-
ously. Although the molecular characteristics of a cancer are, 
in some instances, used to gauge the likelihood of a germline 
mutation (e.g., staining for mismatch repair proteins to identify 
patients for Lynch syndrome screening), such testing is primar-
ily performed when clinical characteristics raise suspicion of a 
hereditary disorder (Fig. 2).14 However, tumor genotyping is 
now a standard part of the management of lung cancer (EGFR), 
colon cancer (KRAS), and melanoma (BRAF). Furthermore, mul-
tigene assays for the comprehensive genetic profiling of tumor 
specimens are increasingly in use,15 generating an enormous 
quantity of oncogenomic data. We suspect there may be addi-
tional instances in which such somatic genotyping could identify 
unexpected germline abnormalities, similar to the incidental iden-
tification of a case of germline EGFR T790M in a recent genomic 
analysis of 439 cases of myelodysplastic syndrome.16 Even BRCA 
genotyping may come to be a component of such multigene assays 
if BRCA mutations are validated as predictive of benefit from 
poly ADP ribose polymerase inhibitors.17 our observation sug-
gests that, for instance, patients either with lung tumors harboring 
the EGFR T790M mutation or with ovarian tumors found to har-
bor BRCA mutations (which can be either somatic or germline)18 
would be ideal candidates for subsequent germline testing.
For this analysis, we studied the most clinically rel-
evant germline mutation in EGFR, T790M, which is interest-
ing because of its relatively high prevalence in lung cancer 
patients (at least 1%),7 its unique role in mediating resis-
tance to TKIs,10,11 and the ongoing efforts to therapeutically 
target this mutation.8 A second germline mutation in EGFR, 
V843I, has also been described to be associated with familial 
lung cancer,3 but has not been observed as a somatic muta-
tion in our institutional experience. Given that two variants 
of germline EGFR mutations have been identified to date, we 
suspect there may be additional germline variants yet to be 
discovered that may contribute to lung cancer risk in a portion 
of never-smokers.
In conclusion, we have found that detection of pretreat-
ment EGFR T790M mutations on routine lung cancer genotyp-
ing signals a likelihood of an underlying germline mutation. 
Lung cancer patients harboring baseline EGFR T790M should 
be studied prospectively to better understand germline preva-
lence, familial penetrance, and lifetime lung cancer risk in car-
riers. For example, we note that only two of the five patients 
FIGURE 1. A case of germline T790M associated with indolent lung cancer growth. A, A germline T790M mutation was found 
in one patient who presented with multifocal adenocarcinoma involving the lung. Over 4 years, the patient’s lung nodules 
displayed minimal growth, consistent with the indolent phenotype described in other lung cancers carrying the T790M muta-
tion.11 B, Rebiopsy of the tumor shown (after observation only) identified an EGFR L858R mutation and a pretreatment T790M 
mutation (left). The mutant T790M peak (red) was of equal proportion to the wild-type allele (blue), consistent with the possi-
bility of a germline mutation. After referral to clinical genetics, sequencing of peripheral white blood cell DNA (right) confirmed 
the germline status of the T790M mutation. 
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carrying germline T790M mutations had a family history of 
lung cancer. This suggests either low penetrance of the high-
risk phenotype or development of de novo germline T790M 
mutations in a portion of patients. We favor the latter expla-
nation given that one of the patients with no family history 
of lung cancer clearly exhibited a high-risk phenotype with 
multiple synchronous EGFR-mutant lung cancers. It is clear 
that a registry for the prospective study of these patients and 
their families is needed, and is under development, to identify 
screening and counseling strategies for this rare but poten-
tially high-risk population.
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FIGURE 2. A possible new strategy for the 
identification of “at risk” probands before 
referral for germline testing. Traditionally, clin-
ical characteristics such as young age, a family 
history of cancer, or multiple primary cancers 
have been used to identify patients at risk of 
carrying germline mutations (left). For some 
cancers, such as colorectal cancer, suspicion 
for Lynch syndrome leads first to molecular 
testing (staining for mismatch repair proteins) 
before germline testing (middle). We propose 
that, for lung cancer, merely the presence of 
pretreatment T790M on EGFR genotyping 
performed for treatment planning could be  
sufficient to lead to germline testing (right).
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